Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

AstraZeneca R&D VP Steve Yang On Building R&D Success In Emerging Markets: An Interview With PharmAsia News (Part 2 of 2)

This article was originally published in PharmAsia News

Executive Summary

The global pharma market in the next five years is expected to grow 3-6% compared to 6.2% in the past five years, while emerging markets will drive major growth and will hold 28% of global spending on medicines by 2015.

You may also be interested in...



MNCs Look To China For Fresh R&D Models, Different Approaches

China’s pharma market offers a chance to try out new R&D models and a different approach to doing business, but local partners are required, said speakers during the inaugural Shanghai CEO Conference.

GSK Establishes Discovery Unit For Traditional Chinese Medicine

GSK transforms DPU in Shanghai into TCM discovery unit that will consist of a small number of select scientists with both Western drug discovery experience and TCM knowledge.

Pfizer's Salomon Azoulay And Bing Yan On Prevenar, Partnering In China Post-Lipitor: An Interview With PharmAsia News (Part 2 of 2)

Pfizer Inc. CEO Ian Read recently affirmed Pfizer's commitment to emerging markets, choosing to keep its established products unit in-house even as he looks to divest non-core assets like the animal health and nutrition business units. Just one week after the announcement of Read's plan, Salomon Azoulay, Pfizer's senior VP for medical & development emerging markets, and Pfizer China Vaccines Lead Bing Yan sat down with PharmAsia News' Shanghai Bureau to talk about Pfizer's blockbuster vaccines Prevenar and Prevenar 13 - marketed in the U.S. as Prevnar - in what will be the world's largest vaccines market. Azoulay was in town to explore partnerships in China, a topic he also discusses in this interview, as well as the importance of physician education in emerging markets.

Related Content

Latest News
See All
UsernamePublicRestriction

Register

SC078307

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel